AstraZeneca to Buy China's Gracell Bio for up to $1.2 Billion https://ift.tt/DujJaOk cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.
NSE IFSC-SGX Connect may be fully operational by June https://ift.tt/XC89Iks this connectivity, global investors who are clients of SGX will be able to trade in Indian derivatives market remotely without having to set up a shop in India. Currently, only a few trades are being executed through the route.
Comments
Post a Comment